Report from the 10th International AIDS Society Conference on HIV Science 21–24 July 2019 Mexico City, Mexico

Shaun Watson
Clinical Nurse Specialist (HIV Community) , Chelsea and Westminster NHS Trust , London

This year ’ s International AIDS Society (IAS) conference ‘IAS19’ was held in Mexico City, a place that despite the danger warnings, was colourful, vibrant, friendly and culturally fascinating. It ’ s great to be here but this is no jolly holiday as sessions start at 07:00 and end at 20:30, for most of us it ’ s a 45-minute taxi ride in as the conference centre is at the edge of a very car-heavy city. IAS19 delivered a lot of new data with the long-awaited news on the potential link between dolutegravir and neural tube birth defects, new antiretroviral therapy (ART), especially the simplifi cation of treatment regimens with fewer drugs, fewer weekly doses, studies on implants and injectable drugs. There were also reports on real-world studies of pre-exposure prophylaxis (PrEP) implementation around the world, particularly how long people stay on PrEP, and advances towards both a prevention vaccine and long-term remission of HIV. For this feedback article I ’ ll focus on the main headline grabbers and my favourite sessions. Read more…